PT-141 (Bremelanotide) Accelerated Titration: Doses, Schedule, and Safety
HealthRX.com
Vyleesi has one dose and no titration schedule
Key numbers
- 1.75 mgLabeled Vyleesi dose: a single 1.75 mg subcutaneous dose taken as neededSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 24 hoursMinimum gap between Vyleesi doses: no more than one dose within this periodSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 8 doses per monthMonthly dose limit: the label says more than this amount is not recommendedSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 40.0%Nausea rate in Vyleesi-treated women in pooled phase 3 trials, versus 1.3% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Bremelanotide
At a glance
- Approved product / Vyleesi 1.75 mg prefilled autoinjector [1]
- Approved dose / 1.75 mg subcutaneous, as needed [1]
- Timing / at least 45 minutes before anticipated sexual activity [1]
- Limits / no more than one dose per 24 hours; more than 8 doses a month not recommended [1]
- Lower doses studied / 0.75, 1.25 and 1.75 mg as fixed doses in phase 2 [2]
- Nausea / 40% overall; 21% after the first dose, about 3% later [1]
What the label says
The label gives one dose: 1.75 mg subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity [1]. It says patients should not administer more than one dose within 24 hours, and that administering more than 8 doses per month is not recommended [1]. Vyleesi is self-administered with a prefilled autoinjector pen [1]. The label describes no lower starting dose or step-up schedule [1].
Questions worth asking
Where 0.75 and 1.25 mg come from
A 12-week phase 2 dose-finding trial randomized premenopausal women with female sexual dysfunction to placebo or bremelanotide 0.75, 1.25 or 1.75 mg subcutaneously as desired, with efficacy data on 327 patients [2]. Nausea, flushing and headache were the reported adverse events [2]. The trial compared fixed doses, not a step-up sequence [2]. The phase 3 registration trials used 1.75 mg as needed for 24 weeks [1][3].
Tolerability at the labeled dose
In the pooled phase 3 trials, nausea occurred in 40.0% of Vyleesi-treated women versus 1.3% on placebo; it was reported by 21% after the first dose and about 3% after later doses [1]. In a phase 4 single-dose study of 228 healthy women, 8 mg oral ondansetron taken 30 minutes before a 1.75 mg dose did not reduce nausea, and the label says this pre-treatment is not recommended [1].
Blood pressure and dosing frequency
The label reports maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with values usually back to baseline within 12 hours [1]. In an 8-day study of 127 women, mean daytime rises were 1.9 mmHg systolic and 1.7 mmHg diastolic [1]. The label says to consider cardiovascular risk and ensure blood pressure is well controlled before starting and periodically during treatment; it says Vyleesi is not recommended for patients at high risk of cardiovascular disease and is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [1]. On dosing frequency, the label says more frequent dosing increases the risk of focal hyperpigmentation and the length of time per month when blood pressure is increased [1]. Focal hyperpigmentation was reported in 1% of patients given up to 8 doses a month in the placebo-controlled phase 3 trials, versus none on placebo [1].
Compounded products
Compounded and research-use PT-141 products are not Vyleesi and are not FDA-approved; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [4][5].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
How many doses of PT-141 can you use in a month?
Does ondansetron prevent nausea from bremelanotide?
Is compounded PT-141 the same as Vyleesi?
References
Show all 5 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325-37.
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.
- Official web page.
- Compounding and the FDA: Questions and Answers | FDA.